Evidence map›Paper›PMID 27018169›Full record

ArticleJournal of cellular biochemistry2016

Biotechnological Chondroitin a Novel Glycosamminoglycan With Remarkable Biological Function on Human Primary Chondrocytes.

Antonietta Stellavato, Virginia Tirino, Francesca de Novellis, Antonella Della Vecchia, Fabio Cinquegrani, Mario De Rosa, Gianpaolo Papaccio, Chiara Schiraldi

Open access · bronzeAbstract read
In one paragraph

Article in Journal of cellular biochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Antonietta StellavatoDepartment of Experimental Medicine, Section of Biotechnology, Medical Histology and Molecular Biology "A. Cascino," Second University of Naples, Naples, Italy.
Virginia TirinoDepartment of Experimental Medicine, Section of Biotechnology, Medical Histology and Molecular Biology "A. Cascino," Second University of Naples, Naples, Italy.
Francesca de NovellisDepartment of Experimental Medicine, Section of Biotechnology, Medical Histology and Molecular Biology "A. Cascino," Second University of Naples, Naples, Italy.
Antonella Della VecchiaDepartment of Experimental Medicine, Section of Biotechnology, Medical Histology and Molecular Biology "A. Cascino," Second University of Naples, Naples, Italy.
Fabio Cinquegranidei Pellegrini Hospital, Naples, Italy.
Mario De RosaDepartment of Experimental Medicine, Section of Biotechnology, Medical Histology and Molecular Biology "A. Cascino," Second University of Naples, Naples, Italy.
Gianpaolo PapaccioDepartment of Experimental Medicine, Section of Biotechnology, Medical Histology and Molecular Biology "A. Cascino," Second University of Naples, Naples, Italy.
Chiara SchiraldiDepartment of Experimental Medicine, Section of Biotechnology, Medical Histology and Molecular Biology "A. Cascino," Second University of Naples, Naples, Italy.
University of Naples Federico II · ITUniversity of Campania "Luigi Vanvitelli" · ITOspedale dei Pellegrini · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cartilage tissue engineering, with in vitro expansion of autologus chondrocytes, is a promising technique for tissue regeneration and is a new potential strategy to prevent and/or treat cartilage damage (e.g., osteoarthritis). The aim of this study was (i) to investigate and compare the effects of new biotechnological chondroitin (BC) and a commercial extractive chondroitin sulfate (CS) on human chondrocytes in vitro culture; (ii) to evaluate the anti-inflammatory effects of the innovative BC compared to extractive CS. A chondrogenic cell population was isolated from human nasoseptal cartilage and in vitro cultures were studied through time-lapse video microscopy (TLVM), immunohistochemical staining and cytometry. In order to investigate the effect of BC and CS on phenotype maintainance, chondrogenic gene expression of aggrecan (AGN), of the transcriptor factor SOX9, of the types I and II collagen (COL1A1 and COL1A2), were quantified through transcriptional and protein evaluation at increasing cultivation time and passages. In addition to resemble the osteoarthritis-like in vitro model, chondrocytes were treated with IL-1β and the anti-inflammatory activity of BC and CS was assessed using cytokines quantification by multiplex array. BC significantly enhances cell proliferation also preserving chondrocyte phenotype increasing type II collagen expression up to 10 days of treatment and reduces inflammatory response in IL-1β treated chondrocytes respect to CS treated cells. Our results, taken together, suggest that this new BC is of foremost importance in translational medicine because it can be applied in novel scaffolds and pharmaceutical preparations aiming at cartilage pathology treatments such as the osteoarthritis. J. Cell. Biochem. 117: 2158-2169, 2016. © 2016 The Authors. Journal of Cellular Biochemistry Published by Wiley Periodicals, Inc.

Indexed as

Gene Expression RegulationAntigens, DifferentiationCells, CulturedChondrocytesChondroitinHumansTissue ScaffoldsAntigens, DifferentiationChondroitinBIOTECHNOLOGICAL CHONDROITINCHONDROITIN SULFATEECM BIOMARKERSINFLAMMATION IN VITRO MODELNASAL CHONDROCYTESTIME-LAPSE VIDEOMICROSCOPY

Identifiers

PMID27018169
PMCPMC5084766
OpenAlexW2334040429

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.